Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
White people who have types of skin cancer other than melanoma may be at increased risk of having other forms of cancer in the future, according to a new study.
The FDA has designated Merck's lambrolizumab (MK-3475) as Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor.
Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
The incidence of pediatric melanoma has increased by about 2% per year, and this incidence trend is influenced by gender, age, and stage at diagnosis, primary site, and UV-B exposure.
Women who take aspirin have a reduced risk of developing melanoma, according to a new observational study. Further, the longer they take it, the lower the risk declines.
Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response.
People with particular variations in a stretch of DNA within the FTO gene, called intron 8, could be at greater risk of developing melanoma.
For postmenopausal Caucasian women, aspirin use is associated with a significantly reduced risk of melanoma.
The gene TP63 is unexpectedly expressed in some melanoma tumors and correlates significantly with a worse prognosis.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|